¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"restriction analysis"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
clonal analysis
Ŭ·ÐºÐ¼®
cluster analysis
¹«¸®ºÐ¼®
cohort analysis
ÄÚȣƮºÐ¼®
computer-assisted semen analysis
ÄÄÇ»ÅÍÁ¤¾×°Ë»ç
computerized image analysis
ÄÄÇ»ÅÍ¿µ»óºÐ¼®
control analysis
ÁöµµºÐ¼®
cost-benefit analysis
ºñ¿ëÆíÀͺм®
cost-effectiveness analysis
ºñ¿ëÈ¿°úºÐ¼®
cost-efficiency analysis
ºñ¿ëÈ¿À²ºÐ¼®
cost-utility analysis
ºñ¿ëÈ¿¿ëºÐ¼®
case analysis
»ç·ÊºÐ¼®, Áõ·ÊºÐ¼®
decision analysis
ÀÇ»ç°áÁ¤ºÐ¼®
discriminant analysis
ÆÇº°ºÐ¼®
distributive analysis
ºÐÆ÷ºÐ¼®
gastric analysis
À§¾×°Ë»ç
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
1
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
self-analysis
ÀÚ±âºÐ¼®
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
clinical decision analysis
ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
clonal analysis
Ŭ·ÐºÐ¼®
cluster analysis
¹«¸®ºÐ¼®
cohort analysis
ÄÚȣƮºÐ¼®
computer-assisted semen analysis
ÄÄÇ»ÅÍÁ¤¾×°Ë»ç
computerized image analysis
ÄÄÇ»ÅÍ¿µ»óºÐ¼®
control analysis
ÁöµµºÐ¼®
cost-benefit analysis
ºñ¿ëÆíÀͺм®
cost-effectiveness analysis
ºñ¿ëÈ¿°úºÐ¼®
cost-efficiency analysis
ºñ¿ëÈ¿À²ºÐ¼®
cost-utility analysis
ºñ¿ëÈ¿¿ëºÐ¼®
decision analysis
ÀÇ»ç°áÁ¤ºÐ¼®
discriminant analysis
ÆÇº°ºÐ¼®
distributive analysis
ºÐÆ÷ºÐ¼®
gene analysis
À¯ÀüÀںм®
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
gasometric analysis
±âüÁ¤·®ºÐ¼®.
gastric analysis
À§¾×°Ë»ç(¡ËþÞÛ).
gene analysis
À¯ÀüÀںм®(¡ÝÂà°).
gene analysis
À¯ÀüÀںм®.
gravimetric analysis
Áß·®ºÐ¼®(ñìÕáÝÂà°).
gravimetric analysis
Áß·®ºÐ¼®
image analysis
¿µ»ó ºÐ¼®
immunochemical analysis
¸é¿ªÈÇÐÀû ºÐ¼®
immunofixation analysis
¸é¿ª°íÁ¤ºÐ¼®
immunoglobulin subgroup analysis
¸é¿ª±Û·ÎºÒ¸°¾ÆÇüºÐ¼®
indirect analysis
°£Á¢ºÐ¼®.
infrared spectroscopic analysis
Àû¿Ü¼± ºÐ±¤ ºÐ¼®
inorganic analysis
¹«±âºÐ¼®(¡ÝÂà°).
plasma analysis
Ç÷ÀåºÐ¼®
polarimetric analysis
Æí±¤ºÐ¼®(ÊÙËÓËÛ).
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
restriction fragment length polymorphism,in cystic fibrosis
³¶¼º¼¶À¯Áõ(ÀÇ)¡(Ò¥àõàéë«ñø¡)
restriction fragment length polymorphism=RFLP
Á¦ÇÑÀýÆí±æÀ̴پ缺
restriction map
Á¦ÇÑÈ¿¼ÒÁöµµ
restriction, H-2
H-2 Â÷À̼ö¹Ý ¸é¿ª»óÈ£ÀÛ¿ëÁ¦ÇÑ
restriction, Ia
IaÂ÷À̼ö¹Ý ¸é¿ª»óÈ£ÀÛ¿ëÁ¦ÇÑ
restriction, MHC
MHCÂ÷À̼ö¹Ý ¸é¿ª»óÈ£ÀÛ¿ëÁ¦ÇÑ
restriction, genetic
À¯ÀüÀû »óÈ£ÀÛ¿ëÁ¦ÇÑ
sleep position restriction
¼ö¸éÀÚ¼¼Á¦ÇÑ
sleep restriction therapy
¼ö¸éÁ¦ÇÑ¿ä¹ý
activation analysis
¹æ»çȺм®, Ȱ¼ºÈºÐ¼®
activation analysis
Ȱ¼ºÈºÐ¼®(¡ÝÂà°), ¹æ»çÈ(Û¯ÞÒûù)ºÐ¼®.
amniotic fluid analysis
¾ç¼öºÐ¼®
analysis
ºÐ¼®
analysis of variance technique
ºÐ»ê±â¼úºÐ¼®
analysis, antigen
Ç׿øºÐ¼®
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½